SOHM INC - SHMN STOCK NEWS

SOHM Inc (OTC PINK:SHMN) has received a patent allowance from Japan's Patent Office for its ABBIE Genome Editing technology. The patent (No. 2023-121860) protects SOHM's innovative SAGE (SOHM-ABBIE Genome Editing) products and services, which enable precise DNA alterations without causing double-stranded breaks. This technology advancement positions SOHM competitively in the global Cell Therapy market, valued at $4.5 Billion in 2023 and projected to reach $97 Billion by 2033. The company plans to expand its presence in Japan, Korea, China, EU, and other global markets through product sales, services, and strategic partnerships.

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has appointed Dr. David Zarling as its Senior Product Development Advisor. Dr. Zarling brings extensive experience in biotechnology, pharmaceuticals, and nutraceuticals, having served in advisory roles at SRI International-BioSciences Division, Pangene , and Colby Pharmaceutical Company. His expertise spans product development, strategic partnering, and innovation in biologic and pharma drug solutions.

Dr. Zarling's background includes work in oncology, immunology, inflammation, infectious and neurodegenerative diseases. His appointment is expected to contribute to SOHM's product development, marketing, and sales efforts, including the company's ABBIE technology products. CEO Baron Night expressed confidence that this addition will help achieve higher revenue growth in 2024 compared to previous years.

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has filed a new provisional patent application with the USPTO. The application, titled 'DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING', describes specific combinations of guide RNAs used with the ABBIE system to increase targeting and efficiency.

This development comes ten months after SOHM's announcement of their 'SMART' gene editing provisional application. The company aims to expand its patent portfolio in the cell engineering space, with the goal of becoming a significant player and leader in gene editing technology and products.

Dr. David Aguilar, COO of SOHM, expressed satisfaction with the progress in developing the ABBIE system and its potential, stating that these technical advances provide the competitive edge needed in this highly contested field.

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced receiving pre-launch orders for their ABBIE Technology kits. This marks a significant milestone as the company transitions from R&D to commercialization of GLP ABBIE Technology Kits. The CRISPR/Cas9 kits market is projected to reach $17.4 billion by 2032.

SOHM's ABBIE technology offers faster and more efficient integration of genetic sequences into cell DNA compared to traditional methods, reducing time and costs. The company's data shows that ABBIE expressing mRNA with guide RNAs integrates donor DNA more efficiently than without guide RNAs.

Management is confident that these pre-launch orders will open new opportunities for their technology. They plan to share updates on collaborations, including one with Stanford Medicine. SOHM aims for higher revenue growth in 2024, partly driven by the new ABBIE kits.

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Senior Cell Engineer and Biochemist. Dr. Kawamura brings extensive experience in biochemistry, molecular biology, and cellular biology. He has a proven track record in developing new methods for cell model creation, protein expression, and DNA/RNA production. Notably, Dr. Kawamura has authored patents in gene editing technology, including SOHM's ABBIE technology.

Dr. Kawamura's appointment is expected to enhance SOHM's scientific capabilities and support the advancement and commercialization of their ABBIE gene editing technology. The company anticipates that his expertise will aid in the timely release of ABBIE kits, as previously announced for the current quarter.

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has signed a manufacturing and supply agreement for skincare topical products with new export customers. The company has dispatched its first initial purchase order of 7,500 units to a new Far East customer, which is expected to generate over a quarter million in revenue during 2024. SOHM's Carlsbad facility will handle production for ongoing regular orders.

The agreement covers human prescription topical treatments for skin care, acne, exfoliation, and anti-aging. SOHM plans to expand its business through private label agreements and CDMO activities with other domestic and export customers. The company aims to capture a substantial market share in 2024, building on its success with other product lines, including the recently introduced ABBIE kits.

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced a new collaboration with Stanford University. This partnership aims to advance cell engineering and gene editing through SOHM's ABBIE Technology. The collaboration will involve joint research projects, knowledge-sharing initiatives, and technology development programs.

Dr. David Aguilar, COO of SOHM, expressed excitement about the partnership, stating that it will amplify their impact and foster innovation. Specific projects and initiatives under this collaboration are expected to be unveiled in the coming months. This strategic alliance combines SOHM's innovative prowess with Stanford's expertise to tackle challenges in gene editing development.

SOHM has announced promising preliminary data from their ABBIE genome editing technology, showcasing successful engineering of a CAR-T cell from a healthy donor that killed lung cancer cells in experimental models. This breakthrough, presented at the 2024 AACR conference, highlights ABBIE's novel approach, utilizing mRNA or purified protein delivery instead of traditional virus-based systems. This could offer a more efficient and less toxic method for developing cancer immunotherapies. The market for such therapies is projected to grow significantly, with CAR T-cell therapy costs ranging from $373,000 to $475,000 per patient.

SOHM targets the release of its revolutionary ABBIE genome editing kits by Q3 2024. ABBIE, a retroviral integrase with a linked dCas9 DNA binding domain, promises precise and targeted integration of donor DNA into cell genomes. This breakthrough technology could significantly advance genetic engineering, offering new treatment possibilities for genetic diseases and novel therapies. The company expects high demand and significant revenue from the first generation of ABBIE kits, projecting thousands of units sold and millions in revenue. Additional related products are also under development.